Market Overview

J.P. Morgan Reiterates Overweight Rating on Pfizer

Related PFE
#PreMarket Movers From December 18, 2014: Rite Aid, Oracle, GoPro And More
Opko Health Inks Pfizer License Pact
Divided Government Won't Halt Street's Run (Fox Business)

In a report published Monday, J.P. Morgan & Co. reiterated its Overweight rating on Pfizer (NYSE: PFE).

J.P. Morgan noted, “Maintain Overweight rating. We see Pfizer offering an attractive mix of 1) inexpensive valuation (11x '13 EPS), 2) an approaching nearterm new product cycle with 3) a high FCF/dividend yield, and 4) limited earnings risk, in our view. We see Pfizer's business unit divestitures as potentially unlocking significant value and anticipate continued high levels of capital return to shareholders, including what we forecast will be $10+ billion of share repurchase in 2013.”

Pfizer closed on Friday at $24.89.

Latest Ratings for PFE

DateFirmActionFromTo
Dec 2014Deutsche BankMaintainsBuy
Oct 2014JefferiesMaintainsBuy
Aug 2014Deutsche BankInitiates Coverage onBuy

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: J.P. Morgan & Co.Analyst Color Reiteration Analyst Ratings

 

Related Articles (PFE)

Around the Web, We're Loving...

Get Benzinga's Newsletters